Net Product Revenue: Increased from $7.1 million in Q3 2025 to $9.1 million in Q4 2025. Prescription Growth: 129% increase in prescriptions from 2,716 units in Q3 to 6,232 units in Q4. Cost of Goods ...

Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Fintel reports that on February 27, 2026, Piper Sandler initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation. As of February 26, 2026, the average one-year price ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

PTHS is trading in the middle of its 52-week range and near its 200-day simple moving average. Price change The price of PTHS shares has decreased $2.48 since the market last closed. This is a 8.73% ...